Pharmacogenomics (PGx) has emerged as a robust, cost-savings, and improvement strategy for employers, payers, providers and patients. What’s more, when implemented across an entire healthcare system, the outcome will be particularly effective. PGx testing provides meaningful data that can help prevent adverse drug reactions, deliver treatments faster, and lower costs.
By lowering high drug spending and adverse side effects, PGx helps healthcare systems avoid downstream ER visits, hospitalizations, and healthcare errors, which translates into substantial improvements in operational, patient care, and cost efficiencies.
During this webinar, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences (CLS) shares how pharmacogenomics can enhance current wellness and medication risk management programs. Attendees will learn important factors to consider when implementing a pharmacogenomics program across a large population of members as will prescribing physicians who are uninformed on the practice of genetics for personalized prescribing.
“When we consider the health and wellness of our society, our pharmacists are already thinking holistically. We can empower them with decision support tools to view all this information in one place so they can adjust medication action plans accordingly and efficiently.”
Instead of relying on trial and error, the goal of a comprehensive medication risk management program is to improve Medication Adherence, Medication Appropriateness, and Medication Adverse Reactions (MA3) using PGx-empowered Medication Therapy Management (MTM) from the point of initial care.
Dr. Shaman’s PGx best practices help organizations focus on the Quadruple Aim:
1. Preserving the care team’s wellbeing—by empowering healthcare providers in their treatment decisions
2. Improving quality of care—by optimizing the experience and satisfaction of patients
3. Lowering the cost of care—through reduced unnecessary medication use, ER visits, hospitalizations, and clinical errors
4. Enabling better outcomes—for overall improvement in population health and patient quality of life
To elaborate on the benefits, the webinar discussion includes a case study featuring a population assessment, program implementation, expert pharmacy review, and unique population outcome assessments. Dr. Shaman provides a clear path for implementing an enterprise-wide pharmacogenomics program that includes utilizing CLS’ clinical decision support tool to analyze an individual’s medication action plan (MAP). He also defines key metrics of success that can be utilized to assess outcomes for member populations.
“If you or a loved one were taking a medication that was not effective or even potentially harmful, wouldn’t you want to know? Wouldn’t you want to be able to help?”
Jeffrey Shaman, PhD, MS, the Chief Science Officer at Coriell Life Sciences, oversees research, education, and clinical programs focused on bridging the gap between genetic science and clinical application. He spent years advising cross-functional teams and forged global strategic partnerships with laboratories, academic institutions, public and private self-insured companies, and federal, state, and regional healthcare systems.